Publications by authors named "Mats Hardling"

Claim this Profile
P
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with mutation.
Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, Anna Rehammar, Anna Staffas, Mats Hardling

Leuk Lymphoma· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.
Jan-Erik Johansson, John Bratel, Mats Hardling, Lena Heikki, Ulf-Henrik Mellqvist

Bone Marrow Transplant· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Mats Hardling

Cancer Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen, Astrid Gruber, Evren Alici, Mats Hardling

Cancer Chemother Pharmacol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
Hareth Nahi, Hans Hägglund, Thomas Ahlgren, Per Bernell, Mats Hardling

Haematologica· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Yuan Wei, Mats Hardling, Bob Olsson, Rahil Hezaveh, Anne Ricksten

Ann Hematol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Mats Hardling, Yuan Wei, Lars Palmqvist, Birgitta Swolin, Dick Stockelberg

Med Oncol· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis